Malawi will on Tuesday spearhead large scale pilot tests for the world's most advanced experimental malaria vaccine in a bid to prevent the disease that kills hundreds of thousands across Africa each year.
It aims to immunise 120,000 children aged two years and under to assess the effectiveness of the pilot vaccine and whether the delivery process is feasible.Trade-named Mosquirix, the drug has been developed by British pharmaceutical giant GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative.
"And even if the child survives, malaria can impact every organ, causing brain injury or even kidney issues. Prevention is better than treatment."Malaria is spread to people through the bites of infected female anopheles mosquitoes. "Despite gains over the last decade, we have seen a stagnation in malaria control efforts in recent years," said researcher Jonathan Juliano from the University of North Carolina."New interventions are needed to continue advancing toward elimination."
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: The Straits Times - 🏆 8. / 63 Read more »